Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adolescent

Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
Luque AE, Cohn SE, Park J-G, et al. "Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the." Antimicrob. Agents Chemother.. 2015;59(4):2094-101.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Smith K, Zheng L, Bosch R, et al. "Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174." AIDS Res. Hum. Retroviruses. 2010;26(4):425-32.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Crawford KW, Spritzler J, Kalayjian RC, et al. "Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir." AIDS Res. Hum. Retroviruses. 2010;26(6):635-43.
Stone ND, Dunaway SB, Flexner C, et al. "Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects." Antimicrob. Agents Chemother.. 2007;51(7):2351-8.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
Mugavero MJ, Pence BW, Whetten K, et al. "Childhood abuse and initial presentation for HIV care: an opportunity for early intervention." AIDS Care. 2007;19(9):1083-7.
de Perio MA, Gomez FJ, Frame PT, Fichtenbaum CJ. "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS. 2007;21(16):2252-3.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob. Agents Chemother.. 2013;57(6):2780-7.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
M Villarino E, Scott NA, Weis SE, et al. "Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid." JAMA Pediatr. 2015;169(3):247-55.
Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.

Pages